Cargene
Bin Xia Yang has worked in a variety of roles in the field of research. From 2011 to 2016, they were a Research Scientist, Senior Research Fellow, and Postdoctoral Research Fellow at the Institute of Molecular & Cell Biology. In 2016, they became a Research Associate at the Genome Institute of Singapore. In 2020, they were promoted to Associate Director of Research at Cargene Therapeutics, and in 2022, they were promoted to Director of Research at Cargene Therapeutics.
Bin Xia Yang obtained their Doctor of Medicine (M.D.) from Jilin University-Norman Bethune College of Medicine between 2000 and 2005, graduating with a degree in Clinical Medicine. Bin Xia then went on to pursue a Doctor of Philosophy (Ph.D.) in Haematology at Peking Union Medical College, which they completed in 2010. Additionally, they hold a PhD certification.
This person is not in any offices
Cargene
Cargene is a bio-pharmaceutical company with oligonucleotide therapeutics for cardiovascular, fibrotic and pulmonary diseases.